Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has announced positive top-line results from a Phase II study of ofatumumab combined with bendamustine in untreated and relapsed chronic lymphocytic leukemia (CLL).
Subscribe to our email newsletter
The study included 44 patients with untreated CLL and 53 patients with relapsed CLL. 87% of total patients completed the full treatment course of six cycles.
A 95% overall response rate and 43% complete response rate was noted in patients with previously untreated CLL, while a 74% overall response rate and 11% complete response rate was noted in relapsed CLL.
Genmab chief executive officer Dr Jan van de Winkel said, "These data show encouraging clinical responses in patients treated with ofatumumab plus bendamustine, a commonly used chemotherapeutic agent, in both untreated and relapsed CLL."
Ofatumumab and bendamustine treatment was well-tolerated by patients in the study.
The most commonly reported adverse reactions include neutropenia, nausea, rash, pyrexia and thrombocytopenia.